20 Apr 2022 --- Aptar CSP Technologies is introducing local production of its Activ-Vial blood glucose test strip protection to diabetes patients in the China region. Activ-Vial will be produced at the company’s facility in Guangzhou, providing a best-in-class offering for the country’s growing diagnostics market, particularly for patients with diabetes conditions where blood glucose monitoring is a critical component of care. By locally manufacturing Activ-Vial, Aptar CSP Technologies will bring production closer to the local customer, mitigating supply chain disruptions and, more importantly, providing an optimal solution to the local diabetes patient.
